Pamela Esposito Replimune Group, Inc. (REPL) insider trading activity

Pamela Esposito is Chief Business Officer of Replimune Group, Inc.. Currently has a direct ownership of 263,436 shares of REPL, which is worth approximately $2.67 Million. The most recent transaction as insider was on Sep 12, 2023, when has been sold 300 shares (Common Stock) at a price of $20.0 per share, resulting in proceeds of $6,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 263K

0% 3M change

0% 12M change

Total Value Held $2.67 Million

Pamela Esposito Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 12 2023	SELL Open market or private sale	$6,000 $20.0 p/Share	300 Reduced 0.11%	263,436 Common Stock
Sep 12 2023	BUY Exercise of conversion of derivative security	$990 $3.3 p/Share	300 Added 0.11%	263,736 Common Stock
Sep 11 2023	SELL Open market or private sale	$107,213 $20.01 p/Share	5,358 Reduced 1.99%	263,436 Common Stock
Sep 11 2023	BUY Exercise of conversion of derivative security	$17,681 $3.3 p/Share	5,358 Added 1.95%	268,794 Common Stock
Aug 22 2023	SELL Open market or private sale	$372,186 $20.01 p/Share	18,600 Reduced 6.59%	263,436 Common Stock
Aug 22 2023	BUY Exercise of conversion of derivative security	$174,840 $9.4 p/Share	18,600 Added 6.19%	282,036 Common Stock
Aug 11 2023	SELL Open market or private sale	$28,000 $20.0 p/Share	1,400 Reduced 0.53%	263,436 Common Stock
Aug 11 2023	BUY Exercise of conversion of derivative security	$4,620 $3.3 p/Share	1,400 Added 0.53%	264,836 Common Stock
Jul 10 2023	SELL Open market or private sale	$427,600 $21.38 p/Share	20,000 Reduced 7.06%	263,436 Common Stock
Jul 10 2023	BUY Exercise of conversion of derivative security	$188,000 $9.4 p/Share	20,000 Added 6.59%	283,436 Common Stock
May 16 2023	SELL Open market or private sale	$107,686 $18.05 p/Share	5,966 Reduced 2.21%	263,436 Common Stock
Apr 01 2023	BUY Grant, award, or other acquisition	-	40,000 Added 12.93%	269,402 Common Stock
Dec 09 2022	SELL Open market or private sale	$375,450 $25.03 p/Share	15,000 Reduced 6.14%	229,402 Common Stock
Dec 09 2022	BUY Exercise of conversion of derivative security	$15,150 $1.01 p/Share	15,000 Added 5.78%	244,402 Common Stock
May 16 2022	SELL Open market or private sale	$51,167 $14.59 p/Share	3,507 Reduced 1.51%	229,402 Common Stock
Apr 01 2022	BUY Grant, award, or other acquisition	-	22,750 Added 8.9%	232,909 Common Stock
Aug 05 2021	SELL Open market or private sale	$905,322 $35.09 p/Share	25,800 Reduced 10.93%	210,159 Common Stock
Aug 05 2021	BUY Exercise of conversion of derivative security	$399,900 $15.5 p/Share	25,800 Added 9.86%	235,959 Common Stock
Aug 04 2021	SELL Open market or private sale	$147,000 $35.0 p/Share	4,200 Reduced 1.96%	210,159 Common Stock
Aug 04 2021	BUY Exercise of conversion of derivative security	$65,100 $15.5 p/Share	4,200 Added 1.92%	214,359 Common Stock
Jul 21 2021	SELL Open market or private sale	$415,885 $33.17 p/Share	12,538 Reduced 5.63%	210,159 Common Stock
Jul 21 2021	BUY Exercise of conversion of derivative security	$12,663 $1.01 p/Share	12,538 Added 5.33%	222,697 Common Stock
Jul 20 2021	SELL Open market or private sale	$160,689 $33.05 p/Share	4,862 Reduced 2.26%	210,159 Common Stock
Jul 20 2021	BUY Exercise of conversion of derivative security	$4,911 $1.01 p/Share	4,862 Added 2.21%	215,021 Common Stock
Jul 15 2021	SELL Open market or private sale	$153,502 $33.37 p/Share	4,600 Reduced 2.14%	210,159 Common Stock

Also insider at

KYMR

Kymera Therapeutics, Inc. Healthcare

Pamela Esposito

Chief Business Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REPL shares.

Notify only if

Value

Insider Trading

Get notified when an Replimune Group, Inc. insider buys or sells REPL shares.

Notify only if

Operation

Value

Type

News

Receive news related to Replimune Group, Inc.

Track Activities on REPL

Account